Integrated OTC Stock Leadership

INBP -  USA Stock  

USD 1.08  0.01  0.92%

Integrated Biopharma employes about 143 people. The company is managed by 8 executives with total tenure of roughly 86 years, averaging almost 10.0 years of service per executive having 17.88 employees per reported executive. Analysis of Integrated Biopharma management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Integrated Biopharma future performance.
Please see Risk vs Return Analysis.

Integrated Insiders 

 
Refresh
  Gerald Kay  Chairman
Chairman, CEO and Pres
  Riva Sheppard  President
Executive Vice President Director

Integrated Biopharma Return on Sales

0.0985Share

Integrated Biopharma Management Team Effectiveness

Integrated Biopharma has return on total asset (ROA) of 13.6 % which means that it generated profit of $13.6 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 77.84 %, meaning that it created $77.84 on every $100 dollars invested by stockholders. Integrated Biopharma management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. As of 25th of October 2021, Return on Average Assets is likely to drop to 0.26. In addition to that, Return on Average Equity is likely to drop to 0.72. As of 25th of October 2021, Total Liabilities is likely to grow to about 13.7 M. Also, Current Liabilities is likely to grow to about 10 M
Integrated Biopharma Weighted Average Shares is very stable at the moment as compared to the past year. Integrated Biopharma reported last year Weighted Average Shares of 29.7 Million. As of 25th of October 2021, Weighted Average Shares Diluted is likely to grow to about 33.8 M, while Issuance Purchase of Equity Shares is likely to drop about 20.4 K.

Integrated Biopharma Workforce Comparison

Integrated Biopharma is currently regarded as number one stock in number of employees category among related companies. The total workforce of Packaged Foods industry is currently estimated at about 1,085. Integrated Biopharma retains roughly 143 in number of employees claiming about 13% of equities listed under Packaged Foods industry.

Integrated Biopharma Profit Margins

The company has Profit Margin (PM) of 9.01 %, which can signify that it executes well on its competitive strategies and has good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 8.48 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.08.

Integrated Biopharma Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Integrated Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Integrated Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Integrated Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Integrated Biopharma Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Integrated Biopharma Price Series Summation is a cross summation of Integrated Biopharma price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Integrated Biopharma Notable Stakeholders

An Integrated Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Integrated Biopharma often face trade-offs trying to please all of them. Integrated Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Integrated Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Gerald Kay - Chairman, CEO and PresProfile
Riva Sheppard - Executive Vice President DirectorProfile
Dina Masi - CFO, Sr. VP and SecretaryProfile
Robert Canarick - Independent DirectorProfile
Carl DeSantis - DirectorProfile
Joseph LaPlaca - DirectorProfile
William Milmoe - DirectorProfile
Christina Kay - Executive VP and DirectorProfile

About Integrated Biopharma Management Performance

The success or failure of an entity such as Integrated Biopharma often depends on how effective the management is. Integrated Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Integrated management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Integrated management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Last ReportedProjected for 2021
Return on Average Assets 0.32  0.26 
Return on Average Equity 0.81  0.72 
Return on Invested Capital 0.37  0.31 
Return on Sales 0.12  0.1 
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 143 people.
The data published in Integrated Biopharma's official financial statements usually reflect Integrated Biopharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Integrated Biopharma. For example, before you start analyzing numbers published by Integrated accountants, it's critical to develop an understanding of what Integrated Biopharma's liquidity, profitability, and earnings quality are in the context of the Consumer Defensive space in which it operates.
Please note, the presentation of Integrated Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Integrated Biopharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Integrated Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Integrated Biopharma. Please utilize our Beneish M Score to check the likelihood of Integrated Biopharma's management to manipulate its earnings.

Integrated Biopharma Workforce Analysis

Traditionally, organizations such as Integrated Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Integrated Biopharma within its industry.

Integrated Biopharma Manpower Efficiency

Return on Integrated Biopharma Manpower

Revenue Per Employee419.9 K
Revenue Per Executive7.5 M
Net Income Per Employee37.8 K
Net Income Per Executive676.2 K
Working Capital Per Employee6.4 K
Working Capital Per Executive114.1 K
Please see Risk vs Return Analysis. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Complementary Tools for Integrated OTC Stock analysis

When running Integrated Biopharma price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Is Integrated Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Integrated Biopharma. If investors know Integrated will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Integrated Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Integrated Biopharma is measured differently than its book value, which is the value of Integrated that is recorded on the company's balance sheet. Investors also form their own opinion of Integrated Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Integrated Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Integrated Biopharma's market value can be influenced by many factors that don't directly affect Integrated Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Integrated Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine Integrated Biopharma value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Integrated Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.